Clinical Trial Update: Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating monthly subcutaneous canakinumab in metformin-treated type 2 diabetes patients was terminated, with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis | Conditions: Diabetes Mellitus, Type 2 | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2012-02-20